Analysts Expect Zynerba Pharmaceuticals (ZYNE) Stock to Gain 73%; Rated Strong Buy


Zynerba Pharmaceuticals (ZYNE) stock is up 53.44% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 67 out of a possible 100.

That score is mainly influenced by a long-term technical score of 83. ZYNE’s score also includes a fundamental score of 69. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $21.25. This means analysts expect the stock to add 73.33% over the next 12 months. The short-term technical score for ZYNE is 48.

Click Here to get the full Stock Score Report on Zynerba Pharmaceuticals Inc (ZYNE).

What’s Happening with ZYNE Stock Today

Zynerba Pharmaceuticals Inc (ZYNE) stock has risen 13.52% while the S&P 500 is up 0.23% as of 12:47 PM on Monday, Jul 22. ZYNE is up $1.46 from the previous closing price of $10.80 on volume of 1,834,186 shares. Over the past year the S&P 500 is up 6.29% while ZYNE is up 53.44%. ZYNE lost -$2.61 per share in the over the last 12 months.

Symbols: ZYNE

You May Also Like